Oncology

BridGene Biosciences adds Nobel winner Dr. Bruce Beutler to its board, gaining immense credibility for its mission to create drugs for intractable diseases.

With a $257M war chest and a veteran team, BlossomHill will showcase its innovative pipeline for lung cancer and leukemia at the pivotal JPM conference.

With pivotal Phase 2 data for its non-invasive skin cancer patch due in Q1, Medicus Pharma is advancing a diverse pipeline fueled by AI and strategic acquisitions.

Tango Therapeutics adds seasoned CFO Sung Lee to its board, a strategic move to guide its lead cancer drug, vopimetostat, through late-stage trials.

With its blockbuster drug's patent cliff looming, Merck's leadership faces high stakes at the JPM conference to unveil its strategy for future growth.

With key trials in brain and prostate cancer, Curasight heads to a top investor conference to showcase its dual-action theranostic technology.

With a blockbuster 2025 in the books, Boston Scientific's leadership faces intense scrutiny at upcoming investor events to prove its growth is sustainable.

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

With patent cliffs looming and big bets on M&A, all eyes are on BMS to prove its growth strategy and high-stakes pipeline can deliver in 2026.

Neovii Pharmaceuticals names Frédéric Prince its next CEO, bringing deep oncology and gene therapy experience from Roche to steer its next growth phase.

Dr. Lu Xianping, crowned EY Entrepreneur Of The Year, didn't just invent new drugs; he helped reinvent China's entire pharmaceutical industry.

After a year of major acquisitions and AI-driven innovation, all eyes are on Labcorp's strategic vision for 2026 at the J.P. Morgan Healthcare Conference.

KORU Medical seeks FDA clearance for its FreedomEDGE® system with a key breast cancer drug, signaling a major shift in cancer care delivery.

A pivotal trial for an acute myeloid leukemia drug is delayed for a promising reason: patients are surviving longer than anticipated, fueling cautious optimism.

Sofie Biosciences begins late-stage trials for a novel PET scan targeting aggressive gastrointestinal cancers, a breakthrough that could redefine detection.

Greenwich LifeSciences execs extend their stock lock-up to 6 years, signaling massive confidence in their breast cancer drug showing an 80% recurrence drop.

Adlai Nortye licenses its promising pan-RAS cancer inhibitor to ASK Pharm for Greater China in a deal valued at up to $230 million.

For the 13th consecutive year, Karmanos Cancer Institute is named a top US hospital, a distinction driven by patient safety and women's care preferences.

With backing from AstraZeneca and Pfizer, Beijing’s Syneron Bio is using its AI-driven platform to develop novel drugs for cancer and chronic illness.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.